PGC1-α has become a promising platform for PD therapy as it acts as a key modulator of mitochondrial biogenesis and cellular antioxidant defense, with a prominent effect on dopaminergic neuron function and survival in the SNpc region [98]. Here, PPARGC1A is linked to Parkinson disease.